Plasma-derived nanoparticles
This application relates to nanoparticles, including nanoparticles derived from a plasma, and their use in the formation of conjugates. The nanoparticles can be stably conjugated to a wide variety of second species, forming conjugates which can be used, for example, in therapeutic, diagnostic and experimental methods.
1. A conjugate comprising:
an aggregate comprising two or more nanoparticulate polymers having mean diameters of 1 nm to 50 nm, wherein the aggregate has a mean diameter of 5 nm to 500 nm, and wherein the nanoparticulate polymers are formed from a plasma comprising acetylene; and
at least one species selected from the group consisting of: a pharmaceutical drug, an imaging agent, a photosensitive dye, a cleavable linking molecule, and a hydrocarbon.
2. The conjugate of claim 1 , wherein the aggregate is spherical or generally spherical.
3. The conjugate of claim 1 , wherein the plasma further comprises one or more monomers selected from: an alkene, a cycloalkene, a cycloalkyne, and mixtures thereof.
4. The conjugate of claim 1 , wherein the plasma further comprises at least one gas comprising an element selected from group 15, 16 or 17 of the periodic table, or an inert gas selected from the group consisting of helium, argon, neon, and mixtures thereof.
5. The conjugate of claim 1 , wherein the plasma further comprises N 2 .
6. The conjugate of claim 5 , wherein the aggregate comprises at least one substituent selected from the group consisting of: an amine group, an imine group, a nitric oxide group, a nitrile group, and mixtures thereof.
7. The conjugate of claim 1 , wherein two or more species are coupled to the aggregate.
8. A pharmaceutical composition comprising:
an aggregate comprising two or more nanoparticulate polymers having mean diameters of 1 nm to 50 nm, wherein the aggregate has a mean diameter of 5 nm to 500 nm, and wherein the nanoparticulate polymers are formed from a plasma comprising acetylene; and
at least one species selected from the group consisting of: a pharmaceutical drug, an imaging agent, a photosensitive dye, a cleavable linking molecule, and a hydrocarbon,
and a pharmaceutically acceptable carrier, excipient, or binder.
9. A method of treating a subject suffering from, susceptible to, or displaying one or more symptoms of a disease, disorder, or condition, the method comprising a step of administering:
i) a conjugate comprising:
an aggregate comprising two or more nanoparticulate polymers having mean diameters of 1 nm to 50 nm, wherein the aggregate has a mean diameter of 5 nm to 500 nm, and wherein the nanoparticulate polymers are formed from a plasma comprising acetylene; and
at least one species selected from the group consisting of: a pharmaceutical drug, an imaging agent, a photosensitive dye, a cleavable linking molecule, and a hydrocarbon, or
ii) a pharmaceutical composition comprising the conjugate of i) and a pharmaceutically acceptable carrier, excipient or binder,
to the subject,
wherein the disease, disorder, or condition is selected from the group consisting of:
acute coronary syndrome, an aging-related disease or disorder, an allergic disease or a related condition, Alzheimer's disease, asthma, HIV, antibiotic resistance, atherosclerosis, an autoimmune disease, a bacterial infection, cancer, dementia, depression or a related condition, diabetes, dyslipidemia, hyperlipidemia, hypertension, ichthyosis, an immune disease, a metabolic disease or disorder, a neurological disease or disorder, obesity, Parkinson's disease, pain, rheumatoid arthritis, and a proliferative disease.
10. The conjugate of claim 1 , wherein the aggregate is crosslinked.
11. The conjugate of claim 1 , wherein the at least one species covalently binds to the aggregate.
12. The conjugate of claim 1 , wherein the conjugate further comprises a substrate.
13. The conjugate of claim 12 , wherein the conjugate is present on at least one surface of the substrate.
14. The conjugate of claim 12 , wherein the conjugate is incorporated within the substrate.
15. The conjugate of claim 12 , wherein the conjugate is covalently bound to the substrate.